Results 141 to 150 of about 10,033 (176)

Recombinant ROP8 antigen: diagnostics, immunogenicity, and therapeutic targeting in toxoplasmosis. [PDF]

Front Immunol
Chyb M, Bekier A, Kawka M, Ferra B, Dziadek B, Michlewska S, Dzitko K, Trotsko N, Gatkowska J.   +8 more
europepmc   +1 more source

Unraveling the mechanisms of bone diseases: targeting dendritic cells in osteoimmunology for internal homeostasis balance. [PDF]

Bone Res
Chen Y, Wang S, Chen X, Wu Z, He F, Chen Q.   +5 more
europepmc   +1 more source

Identification of key genes for heart failure in dilated cardiomyopathy in different populations. [PDF]

Front Genet
Yu Y, Xue C, Ji D, Sheng W, Gao X, Wu X, Wu C.   +6 more
europepmc   +1 more source

Extracellular microvesicles from patients with Rheumatoid arthritis promote dendritic cell activation <i>in vitro</i>. [PDF]

Front Immunol
Buttari B, Recalchi S, Riitano G, Capozzi A, Ucci FM, Manganelli V, Fratini F, Profumo E, Garofalo T, Alessandri C, Misasi R, Conti F, Longo A, Sorice M.   +13 more
europepmc   +1 more source

ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 Blockade. [PDF]

Cancer Immunol Res
Andersson H, Uddbäck I, Hermodsson T, Celander M, Krishna Shetty A, Ljung L, Nilsson A, Sundstedt A, von Schantz L, Varas LA, Levin M, Säll A, Weilguny D, Jansson K, Fritzell S, Hägerbrand K, Lindstedt M, Ellmark P.   +17 more
europepmc   +1 more source

The Role of Complement and CD4 T Cells in Preeclampsia and Offspring Neurodevelopment. [PDF]

Curr Opin Physiol
Regal JF, O'Kane CA, Scroggins SM.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia

Leukemia Research, 2009
Soluble CD83 (sCD83), a potent immunosuppressive agent, circulates at elevated levels in some chronic lymphocytic leukemia (CLL) patients. We report that CLL patients with elevated plasma sCD83 levels had significantly shorter (P=0.038) treatment free survival.
B D, Hock, L J, Fernyhough, S M, Gough, A, Steinkasserer, A G, Cox, J L, McKenzie   +5 more
openaire   +4 more sources

Soluble CD83 inhibits human monocyte differentiation into dendritic cells in vitro

Cellular Immunology, 2014
Human CD83 is type I transmembrane glycoprotein, mainly expressed on mature dendritic cells (DCs), so it was first described as a molecular marker for mature DC. However, increasing evidence has demonstrated that CD83 is also an immunomodulatory molecule either its membrane-bound CD83 (mCD83) or soluble CD83 (sCD83) released from DCs. Intriguingly, the
Hongyu, Lin, Shuang, Liang, Zhenyu, Zhong, Jiexia, Wen, Wenyan, Li, Liyue, Wang, Jian, Xu, Fei, Zhong, Xiujin, Li   +8 more
openaire   +4 more sources

The levels of soluble forms of CD21 and CD83 in multiple sclerosis

Journal of Neuroimmunology, 2018
Multiple Sclerosis (MS) is a neuroinflammatory disease of the central nervous system (CNS) in which immune system plays a crucial role in progression of the disease. An enormous amount of research has been shown that immune mediators such as cytokines and chemokines are the culprits of MS propagation suggesting that modulation of such molecules may ...
Sajad, Karampoor, Hamid, Zahednasab, Masoud, Etemadifar, Hossein, Keyvani   +3 more
openaire   +4 more sources

The soluble form of CD83 is present at elevated levels in a number of hematological malignancies

Leukemia Research, 2004
Recombinant forms of soluble CD83 (sCD83) inhibit anti-tumor responses. In this analysis of circulating sCD83 levels we report that although >95% of acute myeloid leukemia (AML) and multiple myeloma (MM) patients have normal or only weakly elevated sCD83 levels, 20% of chronic lymphocytic leukemia (CLL) and 5/7 mantle cell lymphoma (MCL) patients have ...
Barry D, Hock, Lisa F, Haring, Alexander, Steinkasserer, Karen G, Taylor, William N, Patton, Judith L, McKenzie   +5 more
openaire   +4 more sources